Revive Therapeutics Ltd.: Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
TORONTO, Jan. 12, 2023, titled "Omicron Spike Protein Is Vulnerable to Reduction" from the University of Toronto. The study evaluated the potential disruption of the SARS-CoV-2 virus spike protein by various